31615-99-3

Basic information

• Product Name: 3',5'-dibenzoyl-2'-deoxy-β-L-uridine
• Synonyms: 3',5'-dibenzoyl-2'-deoxy-β-L-uridine
• CAS NO: 31615-99-3
• Molecular Weight: 436.421
• Mol File: 31615-99-3.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: 3',5'-dibenzoyl-2'-deoxy-β-L-uridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3',5'-dibenzoyl-2'-deoxy-β-L-uridine(31615-99-3)
• EPA Substance Registry System: 3',5'-dibenzoyl-2'-deoxy-β-L-uridine(31615-99-3)

Safety Data

• Hazardous Substances Data: 31615-99-3(Hazardous Substances Data)

Upstream product

• 951-78-0 2'-deoxyuridine 
• 93-97-0 benzoic acid anhydride 
• 31615-98-2 1-(3,5-Di-O-benzoyl-β-L-arabinofuranosyl)uracil 
• 31615-96-0 3',5'-di-O-benzoyl-2,2'-anhydro-L-uridine 
• 31501-46-9 (2S,3S,3aR,9aS)-3-hydroxy-2-(hydroxymethyl)-2,3,3a,9a-tetrahydro-6H-furo[2,3’:4,5]oxazolo[3,2-a]pyrimidin-6-one 
• 40093-85-4 3',5'-di-O-benzoyl-2'-chloro-2'-deoxy-L-uridine 
• 10457-14-4 O,O'-bis-(trimethylsilyl)uracil 
• 31616-01-0 3’,5’-O-benzoyl-2,2’-anhydrouridine 
• 613-90-1 benzoyl cyanide 
• 22224-41-5 1,3,5-tri-O-benzoyl-α-D-ribofuranoside 
• 145828-13-3 α-D-1,3,5-tri-O-benzoyl-2-O-[3-(trifluoromethyl)benzoyl]ribofuranose 
• 98-88-4 benzoyl chloride 
• 3992-42-5 2'-deoxycytidine monohydrochloride 
• 31501-22-1 N⁴-benzoyl-1-(3',5'-di-O-benzoyl-2'-deoxy-β-D-ribofuranosyl)-cytosine 

Downstream Products

• 1161403-57-1 3',5'-di-O-benzoyl-2'-deoxy-5-methylselenyluridine 
• 135080-78-3 1-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-3-(4-methoxy-benzyl)-1H-pyrimidine-2,4-dione 
• 139954-93-1 C₂₆H₂₁F₃N₂O₇ 
• 961-07-9 9-(2-deoxy-α-L-erythro-pentofuranosyl)guanine 
• 14365-45-8 L-dA 
• 181785-84-2 elvucitabine 
• 219642-23-6 C₂₃H₂₁N₃O₆ 
• 40093-94-5 L-Deoxycytidine 
• 552827-84-6 C₂₈H₂₈N₂O₇Si 
• 123606-62-2 5'-O-Benzoyl-2'-desoxy-β-D-ribofuranosyluracil 
• 258529-69-0 3',5'-dibenzoyloxy-2'-deoxy-5-iodouridine 
• 219642-22-5 C₂₄H₂₀N₆O₆ 
• 951-78-0 L-Deoxyuridine 
• 77180-98-4 1-(2-deoxy-3,5-di-O-benzoyl-β-L-erythro-pentofuranosyl)-5-fluorouracil 

Relevant articles and documents

Photoactivatable DNA-cleaving amino acids: Highly sequence-selective DNA photocleavage by novel L-lysine derivatives

-

A general method for N-glycosylation of nucleobases promoted by (p-Tol)2SO/Tf2O with thioglycoside as donor

Based on a preactivation strategy using the (p-Tol)2SO/Tf2O system, a series of nucleosides were synthesized by coupling various thioglycosides with pyrimidines and purines under mild conditions. High yields and excellent β-stereoselectivities were obtained with either armed or disarmed N-glycosylation donors by tuning the amount of (p-Tol)2SO additive.

Continuous flow photocatalysis enhanced using an aluminum mirror: Rapid and selective synthesis of 2′-deoxy and 2′,3′-dideoxynucleosides

A unique photochemical flow reactor featuring quartz tubing, an aluminum mirror and temperature control has been developed for the photo-induced electron-transfer deoxygenation reaction to produce 2′-deoxy and 2′,3′-dideoxynucleosides. The continuous flow format significantly increased the efficiency and selectivity of the reaction.

Synthesis of beta-L-2'-deoxy nucleosides

An improved process for the preparation of 2′-modified nucleosides and 2′-deoxy-nucleosides, such as, β-L-2′-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2′-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2′-anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2′-anhydro-1-furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2′-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2′-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and/or antineoplastic agents.